The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The conversation discusses enhancing Minoxidil absorption for hair loss treatment using Tretinoin and MSM (Methylsulfonylmethane). The user is seeking sources for Tretinoin and mentions MSM's potential to improve the absorption of topical agents.
The user experienced hair regrowth after using 5% topical minoxidil for over four months, despite initial shedding. They apply it once daily but occasionally skip days due to concerns about collagen production interference.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
The conversation is about finding a pure high molecular weight hyaluronic acid for the scalp after microneedling. A user suggests using a product from The Ordinary.
The user experienced good crown progress in 3 months using finasteride, collagen, vitamins B, C, D, zinc, and dermarolling. They are pleased with the results after a hair transplant on the front and mid scalp.
Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.
Topical Minoxidil and RU58841 can make hair look brittle and thin, possibly due to the propylene glycol in their solutions. Some users experience side effects like heart palpitations with RU58841, while others have no issues.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
A user's experience with hair loss and scalp inflammation, which was alleviated by using RU58841 along with finasteride and dutasteride. A theory of inflammation possibly being a cause of hairloss is also discussed.
High frequency ultrasonography and HR-MRI can help identify hair shedding causes like inflammation and fibrosis. The conversation discusses the potential of using these technologies to evaluate treatments like Verteporfin for hair regeneration.
The efficacy of microneedling for hair regrowth as either a stand-alone therapy or adjunct to Minoxidil, and whether Tretinoin is a safer and more effective option. Replies include personal accounts from users who have had success with microneedling in combination with minoxidil and peptide serums, as well as considerations of technique, depth, and potential scarring.
The conversation is about using RU58841 and microneedling (1.5mm) for hair loss. The user seeks advice on whether to avoid applying RU58841 on microneedling days to prevent it from becoming systemic.
The user reports thicker and fuller hair after using finasteride, topical minoxidil, RU58841, and dermarolling for two years. Consistent lighting is noted as important for progress pictures.
Minoxidil may cause skin aging effects like wrinkles and dark circles, but evidence is mixed. Alternatives like dermarolling and retinol are suggested.
RU58841 is used topically to prevent hair loss by blocking DHT, with suggestions to drink grapefruit juice, take breaks, avoid microneedling, and use lower concentrations to reduce side effects. Users discuss applying it at night to minimize systemic absorption.
The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.
Tretinoin can increase hair follicles and is used alongside minoxidil and finasteride for hair growth, though it may cause skin peeling. Users report varying results, with some experiencing regrowth and others questioning its efficacy for hair.
Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.
Probiotics like L. reuteri ATCC PTA 6475 and B. longum BB536 may improve hair growth and density by reducing inflammation and reversing DHT damage. The user is trialing these probiotics personally, ordering them from the U.S. to Canada, and plans to continue if no adverse effects occur.
A user is considering using compounded Minoxidil with Tretinoin from Medical Wellness Center to improve hair growth. They are also curious about the effects of higher Minoxidil doses and adding Tretinoin to their regimen.
Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.
2-deoxy-D-ribose, a sugar molecule, is found to be 80%-90% as effective as Minoxidil in promoting hair growth, showing potential for alopecia treatment. Concerns include high cost, lack of human studies, and possible side effects like diarrhea and nausea.
The conversation discusses disappointment with the hair loss treatment KX-826 but notes that the company Kintor is still focused on developing and commercializing it, as stated in their 2023 annual report. The user questions the effectiveness of KX-826 in comparison to minoxidil's role in improving hair thickness and appearance.
Tretinoin may enhance minoxidil's effectiveness for those not responding to minoxidil alone, but it could reduce efficacy for some who are already responding to minoxidil. Tretinoin requires careful use, including skin moisturizing and sun protection due to increased sensitivity.
The conversation is about a hair loss serum mix containing 5% capixyl, 3% redensyl, and procapil. The user is asking for recommendations or opinions on the effectiveness of this product.
RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.
Tretinoin may improve minoxidil's effectiveness for hair growth, but results vary; some users report no change or potential hair loss acceleration. Tretinoin is included in some topical hair loss treatments sold by dermatologists and online companies.